Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386871694> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4386871694 abstract "Abstract Background Lipid-lowering therapy is a key strategy to reduce atherosclerotic cardiovascular disease (ASCVD) risk. However, little is known about the burden of lipid-lowering therapy in China. Purpose We aim to simulate the proportion of individuals in need of different lipid-lowering therapy regimens to reach diverse low-density lipoprotein cholesterol (LDL-C) goals based on the ASCVD risk stratification. Methods We used the data from China PEACE Million Persons Project, a national screening project covering 31 provinces in China. The ASCVD risk stratifications and LDL-C goals were based on the 2016 Chinese Guideline for the Management of Dyslipidemia in Adults. Stepwise lipid-lowering therapy (atorvastatin 20 mg, add-on ezetimibe and add-on evolocumab) was simulated by a Monte Carlo model based on individual's LDL-C level. Results We included 2,876,272 participants (89.7% of the screened) who were not receiving lipid-lowering therapy (mean age 55.8±9.9 years; 60.5% women). The proportion of participants at low, moderate, high and very high ASCVD risk were 57.9%, 17.5%, 22.3% and 2.3%, respectively. In individuals at low or moderate risk, 10.5% did not reach the goal of LDL-C<3.4mmol/L; after statin simulation, 99.8% met the goal. In high-risk patients, 49.0% did not reach LDL-C<2.6mmol/L; after statin monotherapy (82.7%), add-on ezetimibe (10.6%) and add-on evolocumab (6.7%), 99.7% met the goal. In very-high-risk patients, 72.2% did not reach LDL-C<1.8mmol/L; while 99.1% met the goal after all patients received the simulation: statin monotherapy (76.5%), add-on ezetimibe (13.0%) and add-on evolocumab (10.5%). In a total of 609,489 participants (21.2% of the overall participants) needing lipid-lowering therapy, 88.5% required statin monotherapy and 11.5% additional non-statin therapy (Figure). Conclusions Moderate-intensity statin therapy is pivotal in the lipid-lowering therapy in China; nearly 10% in need of lipid-lowering therapy required additional non-statin therapy. Funding Acknowledgement Type of funding sources: None." @default.
- W4386871694 created "2023-09-20" @default.
- W4386871694 creator A5004320397 @default.
- W4386871694 creator A5008089079 @default.
- W4386871694 creator A5019147969 @default.
- W4386871694 creator A5025222082 @default.
- W4386871694 creator A5040544458 @default.
- W4386871694 creator A5051832387 @default.
- W4386871694 creator A5080356578 @default.
- W4386871694 creator A5082441047 @default.
- W4386871694 date "2021-10-01" @default.
- W4386871694 modified "2023-09-27" @default.
- W4386871694 title "Atherosclerotic cardiovascular risk and simulation of lipid-lowering therapy in China" @default.
- W4386871694 doi "https://doi.org/10.1093/eurheartj/ehab724.2567" @default.
- W4386871694 hasPublicationYear "2021" @default.
- W4386871694 type Work @default.
- W4386871694 citedByCount "0" @default.
- W4386871694 crossrefType "journal-article" @default.
- W4386871694 hasAuthorship W4386871694A5004320397 @default.
- W4386871694 hasAuthorship W4386871694A5008089079 @default.
- W4386871694 hasAuthorship W4386871694A5019147969 @default.
- W4386871694 hasAuthorship W4386871694A5025222082 @default.
- W4386871694 hasAuthorship W4386871694A5040544458 @default.
- W4386871694 hasAuthorship W4386871694A5051832387 @default.
- W4386871694 hasAuthorship W4386871694A5080356578 @default.
- W4386871694 hasAuthorship W4386871694A5082441047 @default.
- W4386871694 hasBestOaLocation W43868716941 @default.
- W4386871694 hasConcept C126322002 @default.
- W4386871694 hasConcept C142724271 @default.
- W4386871694 hasConcept C1862650 @default.
- W4386871694 hasConcept C2776839432 @default.
- W4386871694 hasConcept C2777482532 @default.
- W4386871694 hasConcept C2778096610 @default.
- W4386871694 hasConcept C2778114629 @default.
- W4386871694 hasConcept C2778163477 @default.
- W4386871694 hasConcept C2778657065 @default.
- W4386871694 hasConcept C2779134260 @default.
- W4386871694 hasConcept C2780072125 @default.
- W4386871694 hasConcept C2780182762 @default.
- W4386871694 hasConcept C2780745583 @default.
- W4386871694 hasConcept C2780948078 @default.
- W4386871694 hasConcept C2909478654 @default.
- W4386871694 hasConcept C43554185 @default.
- W4386871694 hasConcept C71924100 @default.
- W4386871694 hasConceptScore W4386871694C126322002 @default.
- W4386871694 hasConceptScore W4386871694C142724271 @default.
- W4386871694 hasConceptScore W4386871694C1862650 @default.
- W4386871694 hasConceptScore W4386871694C2776839432 @default.
- W4386871694 hasConceptScore W4386871694C2777482532 @default.
- W4386871694 hasConceptScore W4386871694C2778096610 @default.
- W4386871694 hasConceptScore W4386871694C2778114629 @default.
- W4386871694 hasConceptScore W4386871694C2778163477 @default.
- W4386871694 hasConceptScore W4386871694C2778657065 @default.
- W4386871694 hasConceptScore W4386871694C2779134260 @default.
- W4386871694 hasConceptScore W4386871694C2780072125 @default.
- W4386871694 hasConceptScore W4386871694C2780182762 @default.
- W4386871694 hasConceptScore W4386871694C2780745583 @default.
- W4386871694 hasConceptScore W4386871694C2780948078 @default.
- W4386871694 hasConceptScore W4386871694C2909478654 @default.
- W4386871694 hasConceptScore W4386871694C43554185 @default.
- W4386871694 hasConceptScore W4386871694C71924100 @default.
- W4386871694 hasIssue "Supplement_1" @default.
- W4386871694 hasLocation W43868716941 @default.
- W4386871694 hasOpenAccess W4386871694 @default.
- W4386871694 hasPrimaryLocation W43868716941 @default.
- W4386871694 hasRelatedWork W2121581403 @default.
- W4386871694 hasRelatedWork W2292681792 @default.
- W4386871694 hasRelatedWork W2740472173 @default.
- W4386871694 hasRelatedWork W2751210700 @default.
- W4386871694 hasRelatedWork W2751694839 @default.
- W4386871694 hasRelatedWork W2922111129 @default.
- W4386871694 hasRelatedWork W2932844247 @default.
- W4386871694 hasRelatedWork W2954830231 @default.
- W4386871694 hasRelatedWork W4376132285 @default.
- W4386871694 hasRelatedWork W4383342581 @default.
- W4386871694 hasVolume "42" @default.
- W4386871694 isParatext "false" @default.
- W4386871694 isRetracted "false" @default.
- W4386871694 workType "article" @default.